Physician profile
Hanane Chichane
NPI 1689677957
$13,500.43
in general payments reported to CMS, 2019-2025
25 companies · $2,068 in 2025
The $2,068 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $2,036 · 2021: $1,303 · 2022: $1,749 · 2023: $2,531 · 2024: $2,482 · 2025: $2,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,081.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,548.73 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,521.04 | 2019-2025 | Rexulti |
| Abbvie INC. | $1,370.42 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $1,195.36 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $1,099.77 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $855.47 | 2021-2025 | Lybalvi, Aristada |
| Corium, LLC | $692.18 | 2021-2025 | Azstarys |
| Almatica Pharma LLC | $688.63 | 2022-2025 | Loreev Xr, Teriparatide |
| Lundbeck LLC | $610.18 | 2019-2025 | Rexulti |
| Allergan, INC. | $530.56 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $519.49 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $503.40 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $397.21 | 2019-2023 | Jornay Pm |
| Adlon Therapeutics L.P. | $355.77 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $323.96 | 2019-2025 | Spravato |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $267.49 | 2019-2023 | Dyanavel Xr |
| Shire North American Group INC | $216.27 | 2019 | |
| Neurocrine Biosciences, INC. | $196.71 | 2021-2022 | |
| Noven Therapeutics, LLC | $171.09 | 2020-2024 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $163.44 | 2023-2024 | Auvelity |
| Neos Therapeutics, LP | $99.61 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $83.76 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $36.17 | 2022-2023 | Hetlioz, Fanapt |
| Idorsia Pharmaceuticals US INC | $34.53 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $19.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanane Chichane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.